


Quarterly Audit presentation

2021-22 Quarter 2


1st July – 30th September 2021

Presented 2nd November 2021


Oncology



% in TAT	2021-22 Q1	2021-22 Q2
7 day TAT	10	60




% in TAT	2021-22 Q1	2021-22 Q2
5 day	46	43
7 day	11	6




% in TAT	2021-22 Q1	2021-22 Q2
7 days	15	35

Myeloid




% in TAT	2021-22 Q1	2021-22 Q2
7 day	43	49

Monitoring




% in TAT	2021-22 Q1	2021-22 Q2
7 day	26	22

Rare Disease




% in TAT	2021-22 Q1	2021-22 Q2
3 day	86	76
10 day	83 (n=6)	0 (n=2)




NB DDD not included (research)


% in TAT	2021-22 Q1	2021-22 Q2
10 day	46	41




% in TAT	2021-22 Q1	2021-22 Q2
3 day	43 (n=7)	20 (n=5)




% in TAT	2021-22 Q1	2021-22 Q2
3 day	38	10
5 day	100	96
6 day	83	100
7 day	67	40



% in TAT	2021-22 Q1	2021-22 Q2
3 day	0	9



% in TAT	2021-22 Q1	2021-22 Q2
3 day	-	0 (n=2)



% in TAT	2021-22 Q1	2021-22 Q2
3 day	-	-

Core - Hereditary Cancers

